BeyondSpring Pharma (BYSI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of BeyondSpring Pharma (BYSI)

The financial position of BeyondSpring Inc. (BYSI) is under pressure due to stringent regulatory requirements and the risks of repeat trials. Cancer drug development here is accelerating through AI and synthesis automation, although physicians remain indispensable in clinics. The company's price chart shows an EV/EBITDA of 0.00, while the business relies on an asset-light model with outsourced production to optimize research costs.

BYSI BeyondSpring, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

BYSI (beyondspringpharma.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes BeyondSpring Pharma|BYSI - Fair Value Consensus
- market capitalization indicators:
Market Value BeyondSpring Inc|BYSI - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share BeyondSpring|BYSI - Accounting Capitalization|Market Capitalization to Book Value Ratio beyondspringpharma.com|BYSI - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity BeyondSpring Inc.|BYSI - Long-Term Liabilities to Capital|Short-Term Debt to Equity BeyondSpring|BYSI - Company Debts|Debt to Book Capitalization Ratio BeyondSpring Inc|BYSI - Long-Term Debt|Company Short-Term Debts BeyondSpring|Quick Liquidity Indicator beyondspringpharma.com
- business earnings and investment ratios data:
BYSI - Company Net Income|Future Profit BeyondSpring Inc.|BYSI - Company Value to Net Income|Projected Price to Earnings BeyondSpring Inc.|BYSI - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple BeyondSpring Inc|BYSI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BeyondSpring|BYSI - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months beyondspringpharma.com|BYSI - Earnings per share increase in current year|Earnings growth forecast for next year BeyondSpring Inc.
Summary company analytics:BYSI (BeyondSpring Pharma)
Original product of BeyondSpring

The investment attractiveness of BeyondSpring Inc. (BYSI) is based on the supply of neutropenia drugs to clinics and insurance funds. This metric compares the total enterprise value, including debt, with operating profit before taxes and amortization, allowing for an assessment of the real value of assets. Analyzing the EV/EBITDA trend for BeyondSpring Inc. helps determine the fundamental resilience of the business to its credit load.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)